HOSPIRA BORTEZOMIB 2.5 mg powder for injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

hospira bortezomib 2.5 mg powder for injection vial

pfizer australia pty ltd - bortezomib, quantity: 2.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - hospira bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. hospira bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. hospira bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. hospira bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

HOSPIRA BORTEZOMIB 3.5 mg powder for injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

hospira bortezomib 3.5 mg powder for injection vial

pfizer australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - hospira bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. hospira bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. hospira bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. hospira bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

HOSPIRA BORTEZOMIB 3.0 mg powder for injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

hospira bortezomib 3.0 mg powder for injection vial

pfizer australia pty ltd - bortezomib, quantity: 3 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - hospira bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. hospira bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. hospira bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. hospira bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.